MULTIPRONGED IMMUNOTHERAPY
TO CRACK CANCER RESISTANCES
"The one drug, one therapeutic activity dogma is over. Overriding cancer resistances requires acting on multiple targets simultaneously."
TATUM leverages synthetic biology to build a category-defining platform based on engineered phages capable of multitasking immunotherapies to break cancer resistances.
This first-in-class modality triggers full-blown antitumor immune responses providing unparalleled clearance efficacy.
WELCOME TO
IMMUNO-ONCOLOGY 2.0
Founding team
Jean-François is a scientist-entrepreneur at heart. Convinced that synthetic biology will transform the pharmaceutical industry, he co-founded TATUM to revolutionize the immuno-oncology field.
Kevin Neil, PhD
Co-Founder
Kevin, an exceptional synthetic biologist, turned the radically new technological approach developed by TATUM into a reality. He is convinced that applying synthetic biology principles to the engineering of drugs holds great promise.
Sébastien Rodrigue, PhD
Co-Founder
Professor at the Université de Sherbrooke, Sébastien has positioned his laboratory at the forefront of Canadian synthetic biology. His profound desire to have a positive impact on the world led him to imagine the breakthrough technologies.
Business advisors
Dr. Rivière is General Partner and CMO at TVM Capital Life Science a venture capital fund investing in life science. Prior to joining TVM Capital, Dr. Rivière served in senior R&D roles at Aptalis Pharma, Caprion Pharma, Bioniche Life Sciences, Xenon Pharmaceuticals, and Quintiles.
Equity research analyst in the pharma sectors, Pierre has worked for several financial institutions (BGC Partners, Bryan, Garnier & Co, ODDO BHF) and participated in the IPO of Moderna. He currently is Director Equity Analyst Healthcare at UBP, Geneva.
Scientific advisors
Jamie is a world class authority on filamentous phages and peptide vaccines. She pioneered phage display with Prof. George Smith in the early 90s. This work revolutionized the development of therapeutic antibodies and earned the Nobel Prize to Prof. Smith in 2018.
Lyne spent 20 years at ProMetic where she was VP R&D and pre-clinical studies. She successfully brought seven drugs to clinical trials and two of them are now approved. She currently is a consultant in preclinical studies for fibrosis and cancer therapies.
Medical Advisors
Dr. Kaufman is a leading authority in imuno-oncology. He is former president of the Society for Immunotherapy of Cancer and played a key role in the clinical studies of the anti-PD-L1 Avelumab and the T-VEC oncolytic virus. Dr Kaufman is currently the CEO of Ankyra Therapeutics.
Dr. Champiat is head of the Inpatient Unit in the Drug Development Department at the Gustave Roussy Cancer Campus. He is a rising star in the intratumoral therapy field and strong beleiver this administration route will revolutionize the treatment of cancers.
Dr. Gerald Batist is director of the Department of Oncology at the Montréal Jewish General Hospital and director of McGill University’s Centre for Translational Research in Cancer. He works on novel therapeutics and made significant contributions to the development of new cancer treatments.
Let's get in touch.
Are you interested in collaborating with us? Feel free to contact us. We are looking forward to hearing from you!
Join us to create disruptive drugs!
We are constantly looking for talented individuals who are eager to hack biology and develop next-generation drugs.
If you want to join the team at TATUM, please send your CV and motivation letter at:
